[1] Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003;4(Suppl 7):S21–30.
[2] Stewart S, MacIntyre K, MacLeod MM, Bailey AE, Capewell S, McMurray JJ. Trends in hospitalization for heart failure in Scotland, 1990–1996. An epidemic that has reached its peak? Eur Heart J 2001;22(3):209–17.
[3] Cleland JG, Gemmell I, Khand A, Boddy A. Is the prognosis of heartfailure improving? Eur J Heart Fail 1999;1(3):229–41.
[4] Cowie MR,Wood DA, Coats AJ, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart (British Cardiac Society) 2000;83(5):505–10.
[5] Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme — a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24(5):442–63.
[6] Krumholz HM, Parent EM, Tu N, et al. Readmission after
hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997;157(1):99–104.
[7] McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298(17):2009–19.
[8] Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999;137(2):352–60.
[9] Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007;116(13):1482–7.
[10] Konstam MA, Gheorghiade M, Burnett Jr JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297(12):1319–31.
[11] O'Connell JB. The economic burden of heart failure. Clin Cardiol 2000;23(3 Suppl):III6–III10.
[12] Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of
the European Society of Cardiology. Eur Heart J 2005;26(11):1115–40.
[13] Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation
2005;112(12):e154–235.
[14] Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989;261(6): 884–8.
F. Braunschweig et al. / European Journal of Heart Failure 10 (2008) 907–916 915 Downloaded from eurjhf.oxfordjournals.org at Glasgow University Library on June 17, 2011
[15] Nohria A,Mielniczuk LM, Stevenson LW. Evaluation and monitoring of patients with acute heart failure syndromes. Am J Cardiol 2005;96(6A): 32G–40G.
[16] Lewin J, Ledwidge M,O'Loughlin C,McNally C,McDonald K. Clinical deterioration in established heart failure: what is the value of BNP and weight gain in aiding diagnosis? Eur J Heart Fail 2005;7(6):953–7.
[17] Adamson PB, Magalski A, Braunschweig F, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol 2003;41(4):565–71.
[18] Komajda M, Lapuerta P, Hermans N, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 2005;26(16):1653–9.
[19] Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350(21):2140–50.
[20] Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352(15):1539–49.
[21] Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Eng J Med 2005;352(3):225–37.
[22] Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, Boersma E, Simoons M, Jordaens LJ. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J 2006;27(22):2682–8.
[23] Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Eng J Med 2002;346(24):1845–53.
[24] Freemantle N, Tharmanathan P, Calvert MJ, Abraham WT, Ghosh J, Cleland JG. Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction—a systematic review and meta-analysis. Eur J Heart Fail 2006;8(4):433–40.
[25] Wang L, Lahtinen S, Lentz L, et al. Feasibility of using an implantable system to measure thoracic congestion in an ambulatory chronic heart failure canine model. Pacing Clin Electrophysiol 2005;28(5):404–11.
[26] Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation 2005;112(6):841–8.
[27] Vollmann D, Nagele H, Schauerte P, et al. Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure. Eur Heart J 2007;28(15):1835–40.
[28] Maines M, Catanzariti D, Cemin C, Vaccarini C, Vergara G. Usefulness of intrathoracic fluids accumulation monitoring with an implantable biventricular defibrillator in reducing hospitalizations in patients with heart failure: a case–control study. J Interv Card Electrophysiol
2007;19(3):201–7.
[29] Bourge RC, Abraham WT, Adamson PB, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol 2008;51(11):1073–9.
[30] Adamson PB, Conti JB, Smith AL, et al. Reducing events in patients with chronic heart failure (REDUCEhf) study design: continuous hemodynamic monitoring with an implantable defibrillator. Clin Cardiol 2007;30(11):567–75.
[31] Hjalmarson A. Significance of reduction in heart rate in cardiovascular disease. Clin Cardiol 1998;21(12 Suppl 2):II3–7.
[32] Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 2001;103(10):1428–33.
[33] Fantoni C, Raffa S, Regoli F, et al. Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure. JAmColl Cardiol 2005;46(10):1875–82.
[34] Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UKheart).
Circulation 1998;98(15):1510–6.
[35] Adamson PB, Kleckner KJ, VanHout WL, Srinivasan S, Abraham WT. Cardiac resynchronization therapy improves heart rate variability in patients with symptomatic heart failure. Circulation 2003;108(3):266–9.
[36] Braunschweig F, Mortensen PT, Gras D, et al. Monitoring of physical activity and heart rate variability in patientswith chronic heart failure using cardiac resynchronization devices. Am J Cardiol 2005;95(9):1104–7.
[37] Adamson PB, Smith AL, Abraham WT, et al. Continuous autonomic assessment in patients with symptomatic heart failure: prognostic value of heart rate variability measured by an implanted cardiac resynchronization device. Circulation 2004;110(16):2389–94.
[38] Jaarsma T, van derWal MH, Lesman-Leegte I, et al. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med 2008;168(3):316–24.
[39] Cleland JG, Louis AA, Rigby AS, Janssens U, Balk AH. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. J Am Coll Cardiol 2005;45(10):1654–64.
[40] Schoenfeld MH, Compton SJ, Mead RH, et al. Remote monitoring of implantable cardioverter defibrillators: a prospective analysis. Pacing Clin Electrophysiol 2004;27(6 Pt 1):757–63.
[41] Vardas PE, Auricchio A, Blanc JJ, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European
Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association. Eur Heart J 2007;28(18):2256–95.
[42] Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006
guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death — executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006;27(17):2099–140.
[43] Rector TS, Kubo SH, Cohn JH. Patients self-assessment of their heart failure: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Fail 1987;3:198–209.
[44] EuroQol — a new facility for the measurement of health-related quality of life. The EuroQol Group. Health policy (Amsterdam, Netherlands) 1990;16(3):199–208.
[45] Franciosa JA, Taylor AL, Cohn JN, et al. African-American heart failure trial (A-HeFT): rationale, design, and methodology. J Card Fail 2002;8(3):128–35.
[46] Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrica 1981:373–9.